 Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatmentVanessa Neiens,
Eva-Maria Hansbauer,
Thomas J. Jaquin,
Janet K. Peper-Gabriel,
Poornima Mahavadi,
Mark E. Snyder,
Maximilian J. Grill,
Cornelia Wurzenberger,
Antonio Konitsiotis,
Adriana Estrada-Bernal,
Kristina Heinig,
Athanasios Fysikopoulos,
Nicolas Schwenck,
Stefan Grüner,
Denis Bartoschek,
Theresia Mosebach,
Sandra Kerstan,
Joe Wrennall,
Marleen Richter,
Kentaro Noda,
Konrad Hoetzenecker,
Janette K. Burgess,
Robert Tarran,
Claudia Wurzenberger,
Karl-Robert Wichmann,
Jonas Biehler,
Kei W. Müller,
Andreas Guenther,
Oliver Eickelberg,
Mary F. Fitzgerald,
Shane A. Olwill,
Gabriele Matschiner and
Marina Pavlidou ()
Nature Communications, 2025, vol. 16, issue 1, 1-20 Abstract: Abstract Inhaled therapeutics have high potential for the treatment of chronic respiratory diseases of high unmet medical need, such as idiopathic pulmonary fibrosis (IPF). Preclinical and early clinical evidence show that cellular communication network factor 2 (CCN2), previously called connective tissue growth factor (CTGF), is a promising target for the treatment of IPF. In recent phase 3 clinical trials, however, systemic CCN2 inhibition failed to demonstrate a clinically meaningful benefit. Here, we present the preclinical profile of the inhaled anti-CCN2 Anticalin® protein PRS-220. Our study demonstrates that efficient pulmonary delivery directly translates into superior efficacy in relevant models of pulmonary fibrosis when compared to systemic CCN2 inhibition. Moreover, we present a holistic approach for the preclinical characterization of inhaled PRS-220 from state-of-the art in vitro and in vivo models to novel human ex vivo and in silico models, highlighting the advantage of inhaled drug delivery for treatment of respiratory disease. Date: 2025 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58568-x Ordering information: This journal article can be ordered from DOI: 10.1038/s41467-025-58568-x Access Statistics for this article Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie More articles in Nature Communications from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.